New drug developments in the Latin Americas (Argentina, Costa Rica, Mexico and Panama).
New drug developments in four Latin American countries, i.e. Argentina, Costa Rica, Mexico and Panama and the United States were compared. In contradistinction to the United States, clinical investigations with newly developed drugs in the four countries are based on contracts between individual investigators and the pharmaceutical industry without governmental interference. There are no adequate facilities to develop new psychoactive preparation in the four Latin American countries. Nevertheless, psychopharmacological practices are essentially the same as in the United States or Canada and all important psychoactive preparations used in the United States are available in the Latin Americas. Some of the newer-thioxanthene, butyrophenone and diphenylbutylpiperidine preparations which are still under clinical investigation in the United States are already available for clinical use in Argentina, Costa Rica, Mexico and Panama. While there is less governmental control than in the United States or Canada, with regard to clinical investigations of drugs or with regard to marketing newly developed preparations, there is no evidence of abuse. Finally, it should be noted that the introduction of psychotropic drugs brought about a new era in psychiatry in the Latin Americas. It becomes increasingly obvious that psychiatry today is practiced on the basis of knowledge derived from clinical impressions and on the basis of findings verified in clinical testings, i.e. on the basis of two different standards. Accordingly, as in Europe and North America, a re-examination of traditional concepts has begun in the Latin Americas. There are indications that biological psychiatry in general, and psychopharmacology in particular, are gaining increasing importance in the Latin Americas. This has led to the creation of a training program in biological psychiatry by the World Health Organization in Montreal, in cooperation with the Division of Psychopharmacology of the Department of Psychiatry at McGill University.
Ban
T A
TA
W.H.O. Training Program in Biological Psychiatry, Division of Psychopharmacology, Department of Psychiatry, McGill University, Montreal, Canada.
Galvan
L
L
Udabe
R U
RU
Vergara
L
L
Zoch
C
C
D001118:Argentina; D003364:Costa Rica; D015195:Drug Design; D015507:Drugs, Investigational / Q000737:chemistry; D004503:Education, Medical, Graduate; D006801:Humans; D007843:Latin America; D008800:Mexico; D010176:Panama; D011570:Psychiatry / Q000458:organization & administration; D011600:Psychopharmacology / Q000193:education; D011619:Psychotropic Drugs / Q000627:therapeutic use; D000078329:Workforce
D015507:Drugs, Investigational; D011619:Psychotropic Drugs